Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2017-12-20
|
Trimodulin® (IgM Concentrate - IgM enriched immunoglobulin) |
severe community-acquired pneumonia (sCAP) |
2 |
Biotest (Germany) |
Infectious diseases |
2017-12-20
|
bimekizumab |
psoriatic arthritis |
2b |
UCB (Belgium) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2017-12-19
|
OSE-127 (Effi-7) |
inflammatory bowel diseases including Crohn's disease and ulcerative colitis |
preclinical |
OSE Immunotherapeutics (France) |
Autoimmune diseases - Gastrointestinal diseases - Inflammatory diseases |
2017-12-19
|
SHP609 (idursulfase-IT) |
mucopolysaccharidosis II (MPS II, Hunter Syndrome) |
2-3 |
Shire (UK - USA) |
Rare diseases - Genetic diseases |
2017-12-19
|
Traumakine® - FP-1201 (human recombinant interferon-beta 1a) |
Multi-Organ Failure (MOF), prevention of surgically operated Ruptured Abdominal Aorta Aneurysm |
2 |
Faron Pharmaceuticals (Finland) |
Cardiovascular diseases |
2017-12-18
|
cariprazine |
bipolar depression |
3 |
Gedeon Richter (Hungary) Allergan (Ireland) |
CNS diseases - Mental diseases |
2017-12-18
|
HLA-A2 CAR lentiviral vector |
|
preclinical |
Txcell (France) |
Inflammatory diseases |
2017-12-18
|
BION-1301 |
relapsed or refractory multiple myeloma |
1-2 |
Aduro Biotech (USA - CA) |
Cancer - Oncology |
2017-12-18
|
Qarziba®/Isqette® (APN311 - dinutuximab beta) |
neuroblastoma |
|
Apeiron Biologics (Austria) |
Cancer - Oncology |
2017-12-16
|
SEL24 |
acute myeloid leukemia |
1-2 |
Selvita (Poland) |
Cancer - Oncology |
2017-12-15
|
fitusiran (SAR439774 - ALN-AT3) |
hemophilia A, hemophilia B with or without inhibitors |
2 |
Alnylam Therapeutics (USA - MA), Sanofi (France) |
Rare diseases - Genetic diseases - Hematological diseases |
2017-12-15
|
fitusiran (SAR439774 - ALN-AT3) |
hemophilia A and B with or without inhibitors |
3 |
Alnylam Therapeutics (USA - MA), Sanofi (France) |
Rare diseases - Genetic diseases - Hematological diseases |
2017-12-15
|
fitusiran (SAR439774 - ALN-AT3) |
hemophilia A and B with or without inhibitors |
3 |
Alnylam Therapeutics (USA - MA), Sanofi (France) |
Rare diseases - Genetic diseases - Hematological diseases |
2017-12-15
|
fitusiran (SAR439774 - ALN-AT3) |
hemophilia A and B with or without inhibitors |
3 |
Alnylam Therapeutics (USA - MA), Sanofi (France) |
Rare diseases - Genetic diseases - Hematological diseases |
2017-12-14
|
|
hemophilia |
|
Shire (UK - USA) Royal College of Surgeons Ireland (Ireland) Science Foundation Ireland (SFI) (Ireland) Irish Haemophilia Society (Ireland) |
Rare diseases - Genetic diseases - Hematological diseases |
2017-12-14
|
PF-04965842 |
moderate-to-severe atopic dermatitis (AD) |
3 |
Pfizer (USA - NY) |
Autoimmune diseases - Dermatological diseases |
2017-12-13
|
nivolumab and tumor-infiltrating lymphocyte (TIL) |
advanced non-small cell lung cancer (NSCLC) |
1 |
Iovance Biotherapeutics (USA - CA) tumor-infiltrating lymphocyte (TIL) |
Cancer - Oncology |
2017-12-13
|
REGN2810 - cemiplimab |
advanced cutaneous squamous cell carcinoma |
2 |
Regeneron Pharmaceuticals (USA - NY) Sanofi (France) |
Cancer - Oncology |
2017-12-13
|
Trumenba® - rLP2086 coadministered with routine meningococcal (groups A, C, Y and W) (MCV4) and tetanus, diphtheria and pertussis (Tdap) vaccines |
|
3 |
Pfizer (USA - NY) |
|
2017-12-13
|
AVXS-101 (adeno-associated virus serotype 9 expressing the human Survival Motor Neuron gene) |
spinal muscular atrophy (SMA) Type 1 |
1 |
Avexis (USA - IL) |
Rare diseases - Genetic diseases - Neuromuscular diseases |